Bone complications in multiple myeloma

James R. Berenson, Lakshmi Rajdev, Michael Broder

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Multiple myeloma is the malignant proliferation of plasma cells involving more than 10% of the bone marrow. The bone complications associated with multiple myeloma include bone pain, pathologic fractures, hypercalcemia of malignancy and cord compressions. The principal pathophysiology of bone disease in multiple myeloma is a shift in the balance of bone remodeling toward bone resorption. In recent years, bisphosphonates have become an important treatment for the bone complications of multiple myeloma. Potent inhibitors of osteoclast activity, bisphosphonates interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote differentiation of osteoblasts, as well as inhibiting other aspects of osteoclast homeostasis and metabolism. Several studies have evaluated treatment with bisphosphonates in patients with multiple myeloma, and have demonstrated the efficacy of clodronate (Bonefos®; Anthra Pharmaceuticals; Princeton, NJ; www.bonefos.com), pamidronate (Aredia®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.pamidronate.com) and zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.us.zometa.com) in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid.

Original languageEnglish (US)
Pages (from-to)1082-1085
Number of pages4
JournalCancer Biology and Therapy
Volume5
Issue number9
StatePublished - Sep 2006

Fingerprint

pamidronate
zoledronic acid
Multiple Myeloma
Diphosphonates
Clodronic Acid
Bone and Bones
Osteoclasts
Pharmaceutical Preparations
Pain
Spontaneous Fractures
Bone Remodeling
Bone Diseases
Hypercalcemia
Bone Resorption
Plasma Cells
Osteoblasts
Osteogenesis
Homeostasis
Bone Marrow
Apoptosis

Keywords

  • Bisphosphonates
  • Bone
  • Multiple myeloma
  • Sequelae

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Berenson, J. R., Rajdev, L., & Broder, M. (2006). Bone complications in multiple myeloma. Cancer Biology and Therapy, 5(9), 1082-1085.

Bone complications in multiple myeloma. / Berenson, James R.; Rajdev, Lakshmi; Broder, Michael.

In: Cancer Biology and Therapy, Vol. 5, No. 9, 09.2006, p. 1082-1085.

Research output: Contribution to journalArticle

Berenson, JR, Rajdev, L & Broder, M 2006, 'Bone complications in multiple myeloma', Cancer Biology and Therapy, vol. 5, no. 9, pp. 1082-1085.
Berenson JR, Rajdev L, Broder M. Bone complications in multiple myeloma. Cancer Biology and Therapy. 2006 Sep;5(9):1082-1085.
Berenson, James R. ; Rajdev, Lakshmi ; Broder, Michael. / Bone complications in multiple myeloma. In: Cancer Biology and Therapy. 2006 ; Vol. 5, No. 9. pp. 1082-1085.
@article{faa73ed8eeb14b4d9ffc05745c2205c8,
title = "Bone complications in multiple myeloma",
abstract = "Multiple myeloma is the malignant proliferation of plasma cells involving more than 10{\%} of the bone marrow. The bone complications associated with multiple myeloma include bone pain, pathologic fractures, hypercalcemia of malignancy and cord compressions. The principal pathophysiology of bone disease in multiple myeloma is a shift in the balance of bone remodeling toward bone resorption. In recent years, bisphosphonates have become an important treatment for the bone complications of multiple myeloma. Potent inhibitors of osteoclast activity, bisphosphonates interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote differentiation of osteoblasts, as well as inhibiting other aspects of osteoclast homeostasis and metabolism. Several studies have evaluated treatment with bisphosphonates in patients with multiple myeloma, and have demonstrated the efficacy of clodronate (Bonefos{\circledR}; Anthra Pharmaceuticals; Princeton, NJ; www.bonefos.com), pamidronate (Aredia{\circledR}; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.pamidronate.com) and zoledronic acid (Zometa{\circledR}; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.us.zometa.com) in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid.",
keywords = "Bisphosphonates, Bone, Multiple myeloma, Sequelae",
author = "Berenson, {James R.} and Lakshmi Rajdev and Michael Broder",
year = "2006",
month = "9",
language = "English (US)",
volume = "5",
pages = "1082--1085",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "9",

}

TY - JOUR

T1 - Bone complications in multiple myeloma

AU - Berenson, James R.

AU - Rajdev, Lakshmi

AU - Broder, Michael

PY - 2006/9

Y1 - 2006/9

N2 - Multiple myeloma is the malignant proliferation of plasma cells involving more than 10% of the bone marrow. The bone complications associated with multiple myeloma include bone pain, pathologic fractures, hypercalcemia of malignancy and cord compressions. The principal pathophysiology of bone disease in multiple myeloma is a shift in the balance of bone remodeling toward bone resorption. In recent years, bisphosphonates have become an important treatment for the bone complications of multiple myeloma. Potent inhibitors of osteoclast activity, bisphosphonates interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote differentiation of osteoblasts, as well as inhibiting other aspects of osteoclast homeostasis and metabolism. Several studies have evaluated treatment with bisphosphonates in patients with multiple myeloma, and have demonstrated the efficacy of clodronate (Bonefos®; Anthra Pharmaceuticals; Princeton, NJ; www.bonefos.com), pamidronate (Aredia®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.pamidronate.com) and zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.us.zometa.com) in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid.

AB - Multiple myeloma is the malignant proliferation of plasma cells involving more than 10% of the bone marrow. The bone complications associated with multiple myeloma include bone pain, pathologic fractures, hypercalcemia of malignancy and cord compressions. The principal pathophysiology of bone disease in multiple myeloma is a shift in the balance of bone remodeling toward bone resorption. In recent years, bisphosphonates have become an important treatment for the bone complications of multiple myeloma. Potent inhibitors of osteoclast activity, bisphosphonates interfere with biochemical pathways and induce osteoclast apoptosis. Bisphosphonates also antagonize osteoclastogenesis and promote differentiation of osteoblasts, as well as inhibiting other aspects of osteoclast homeostasis and metabolism. Several studies have evaluated treatment with bisphosphonates in patients with multiple myeloma, and have demonstrated the efficacy of clodronate (Bonefos®; Anthra Pharmaceuticals; Princeton, NJ; www.bonefos.com), pamidronate (Aredia®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.pamidronate.com) and zoledronic acid (Zometa®; Novartis Pharmaceuticals Corp; East Hanover, NJ; www.us.zometa.com) in reduction of pain, reduction of SREs and survival. Moreover, recent data suggest direct and indirect antimyeloma activity of pamidronate and zoledronic acid.

KW - Bisphosphonates

KW - Bone

KW - Multiple myeloma

KW - Sequelae

UR - http://www.scopus.com/inward/record.url?scp=33751114397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751114397&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 1082

EP - 1085

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 9

ER -